PT-141 (bremelanotide) is a melanocortin receptor agonist peptide investigated for sexual dysfunction and arousal disorders. It acts centrally to increase sexual desire and genital blood flow independent of nitric oxide pathways.
Notes
PT-141 is not FDA-approved in the United States for general use, though bremelanotide has received FDA approval (Vylessi®) for female sexual arousal disorder in a nasal spray formulation. Research and clinical use outside approved formulations carries regulatory and safety considerations. This guide is for educational harm-reduction purposes only and does not constitute medical advice or endorsement of off-label use.
PT-141 binds to melanocortin receptors (particularly MC1R and MC4R) in the hypothalamus and other central nervous system regions. This activation increases dopamine signaling and autonomic tone, triggering pro-sexual and pro-erectile effects. Unlike PDE5 inhibitors (e.g., sildenafil), it does not rely on peripheral vasodilation alone but works through neuroendocrine pathways to enhance desire and arousal.
PT-141 is a peptide (7-amino acid sequence derived from α-melanocyte-stimulating hormone) administered subcutaneously for rapid absorption. Peak plasma levels occur within 30–60 minutes. It is metabolized by peptidase enzymes and has a short elimination half-life, making it suitable for acute pre-event dosing.
Typical Dose
1.75 mg (0.88 mL of 2 mg/mL solution) per dose; typically used as needed 45 minutes before sexual activity, or per protocol
Frequency
As needed (acute use) or per protocol
Administration
Subcutaneous injection
Half-Life
~1–2 hours
Contraindications